Cargando…
Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine
Intramuscular vaccines have greatly reduced hospitalization and death due to severe COVID-19. However, most countries are experiencing a resurgence of infection driven predominantly by the Delta and Omicron variants of SARS-CoV-2. In response, booster dosing of COVID-19 vaccines has been implemented...
Autores principales: | Lin, Yi-Jiun, Lin, Meei-Yun, Chuang, Ya-Shan, Liu, Luke Tzu-Chi, Kuo, Tsun-Yung, Chen, Charles, Ganesan, Shyamala, Fattom, Ali, Bitko, Vira, Lien, Chia-En |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255510/ https://www.ncbi.nlm.nih.gov/pubmed/35790783 http://dx.doi.org/10.1038/s41598-022-15238-y |
Ejemplares similares
-
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
por: Ganesan, Shyamala, et al.
Publicado: (2022) -
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
por: Liu, Luke Tzu-Chi, et al.
Publicado: (2022) -
Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
por: Cheng, Shu-Hsing, et al.
Publicado: (2022) -
A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
por: Cheng, Shu-Hsing, et al.
Publicado: (2022) -
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
por: Waits, Alexander, et al.
Publicado: (2022)